The results of a recent phase 3 trial have indicated that a treatment combination could serve as a potential alternative to abacavir plus lamivudine in patients with HIV-1 who achieved virological...
The authors of a recent study aimed to estimate the effects of traditional cardiovascular disease prevention interventions on future cardiovascular health outcomes.
It is well known that initial declines in bone mineral density are common with the initiation of antiretroviral therapy. In a new study, researchers assessed risk factors for decline in women and men with...
The US Food and Drug Administration has approved the smallest integrase strand transfer inhibitor-based triple-therapy single tablet regimen for adults with HIV-1.
Individuals with HIV often have a higher risk of age-related morbidity, despite successful antiretroviral therapy. However, less is known about the risk of accelerated cognitive decline or aging-related...
Two-drug regimens for ART are of interest, in order to minimize drug exposure and toxicity. The efficacy, safety, and tolerability of dolutegravir and rilpivirine suggest that they may be good candidates...
Previous evidence has shown that human immunodeficiency virus and antiretroviral therapy are associated with metabolic disturbances. However, less information currently exists regarding the effect of body...
In a recent study, researchers evaluated the safety and immunogenicity of a new double recombinant vaccine for the prevention of human immunodeficiency virus infection.
After the recent approval of Juluca, the first two-drug regimen for HIV, drugmakers are focusing on making new HIV treatments more accessible and convenient.
After 2 clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved the first complete HIV treatment regimen containing only 2 drugs.
